Previous Close | 1.0600 |
Open | 1.0200 |
Bid | 1.0400 x 1000 |
Ask | 1.0900 x 4000 |
Day's Range | 1.0200 - 1.0767 |
52 Week Range | 0.6300 - 4.2800 |
Volume | |
Avg. Volume | 46,156 |
Market Cap | 12.581M |
Beta (5Y Monthly) | 0.19 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.6260 |
Earnings Date | Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.25 |
Subscribe to Yahoo Finance Plus to view Fair Value for INVO
INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its second quarter 2022, ended June 30, 2022, after the market close on Monday, August 15, 2022. The Company has scheduled a conference call that same day, Monday, August 15, 2022, at 4:30 pm ET, to review the results.
INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced that Dr. Sue Ellen Carpenter of Bloom Fertility, an INVO Center in Atlanta, will be hosting "Get to Know INVOcell" - a Facebook Live Event on July 7, 2022 at 7 PM ET.
INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has entered an exclusive distribution agreement with Onesky Holdings Limited ("Onesky") for Mainland China (excludes Hong Kong, Macau and Taiwan).